FY2026 Earnings Forecast for BioSyent Issued By Bloom Burton

BioSyent Inc. (CVE:RX) – Equities research analysts at Bloom Burton reduced their FY2026 earnings per share (EPS) estimates for BioSyent in a report issued on Monday, March 17th. Bloom Burton analyst D. Martin now forecasts that the company will post earnings of $0.88 per share for the year, down from their prior forecast of $0.91. The consensus estimate for BioSyent’s current full-year earnings is $0.69 per share.

BioSyent Price Performance

CVE:RX opened at C$11.25 on Wednesday. The stock has a 50 day moving average of C$11.04 and a two-hundred day moving average of C$11.11. BioSyent has a 12 month low of C$8.24 and a 12 month high of C$12.13. The firm has a market cap of C$128.67 million, a P/E ratio of 18.26 and a beta of 0.93. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90.

Insider Transactions at BioSyent

In other BioSyent news, insider FAX Capital Corp. sold 112,400 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of C$11.28, for a total value of C$1,267,557.28. Corporate insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.